NCT01827644 - Bioavailability and Food Effect of the Original Gelatin Formulation and Two New Formulations of Afuresertib in Normal Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 24, 2013

Primary Completion Date

July 12, 2013

Study Completion Date

July 12, 2013

Conditions

Cancer

Interventions

DRUG

Afuresertib GC - Fasted State

White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fasted state

DRUG

Afuresertib HPMC capsule - Fasted State

White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fasted state

DRUG

Afuresertib ECT - Fasted State

White to off white, round, biconvex coated tablet containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib ECT administered in fasted state

DRUG

Afuresertib GC - Fed State

White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fed state

DRUG

Afuresertib HPMC capsule - Fed State

White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fed state

DRUG

Afuresertib ECT - Fed State

White to off white, round, biconvex coated tablet containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib ECT administered in fed state

Trial Locations (1)

3004

GSK Investigational Site, Melbourne